To improve genetic testing in familial breast cancer, a clinical scoring system (‘Manchester score’) was developed to assess the likelihood of a BRCA1 or BRCA2 GPV variant being present in a family based on the presence of pathological type, age at onset and number of breast and other cancers in close relatives with a threshold score at which genetic testing was recommended (G. R. Evans and Lalloo 2010; D. G. Evans et al. The gene discussed is BRCA2; the disease is cancer.